companydata.dkcompanydata.dk

Y-mAbs Therapeutics A/S: Financial statements 2021

CVR: 37053678

Source: annual report 2021, Danish Business Authority

01/01/2021 – 31/12/2021

Y-mAbs Therapeutics A/S (CVR 37053678) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 67,549,569 and a net result of DKK -42,087,769 compared with DKK -1,202,417 the year before. That is a decrease of 18.1% compared with the year before. Equity in the 2021 report amounted to DKK -39,255,112. The company had 88 employees in the financial year.

Gross Profit
DKK 67,549,569
Profit/Loss
DKK -42,087,769
Equity
DKK -39,255,112
Total Assets
DKK 61,471,927
Employees
88

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2021-67.5M-42.1M-39.3M88
2020-82.4M-1.2M2.8M62
2019-52M-2.6M4M36
2018-28.6M-4.2M1.6M19
2017-13.2M-2.2M808K-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like Y-mAbs Therapeutics A/S

Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.

Try the lead list generator

Events in 2021

Bo Kruse joins the board of Y-mAbs Therapeutics A/SOct 28, 2021

As of October 28, 2021, Bo Kruse has joined the board of directors of Y-mAbs Therapeutics A/S.

Johan Ernst Wedell-Wedellsborg leaves the board of Y-mAbs Therapeutics A/SOct 28, 2021

As of October 28, 2021, Johan Ernst Wedell-Wedellsborg has left the board of directors of Y-mAbs Therapeutics A/S.

Ashutosh Tyagi leaves the board of Y-mAbs Therapeutics A/SOct 28, 2021

As of October 28, 2021, Ashutosh Tyagi has left the board of directors of Y-mAbs Therapeutics A/S.

David Neil Gill leaves the board of Y-mAbs Therapeutics A/SOct 28, 2021

As of October 28, 2021, David Neil Gill has left the board of directors of Y-mAbs Therapeutics A/S.

Jim Irvin Healy leaves the board of Y-mAbs Therapeutics A/SOct 28, 2021

As of October 28, 2021, Jim Irvin Healy has left the board of directors of Y-mAbs Therapeutics A/S.

Gérard Ber leaves the board of Y-mAbs Therapeutics A/SOct 28, 2021

As of October 28, 2021, Gérard Ber has left the board of directors of Y-mAbs Therapeutics A/S.

Laura J. Hamill leaves the board of Y-mAbs Therapeutics A/SOct 28, 2021

As of October 28, 2021, Laura J. Hamill has left the board of directors of Y-mAbs Therapeutics A/S.

Y-mAbs Therapeutics A/S: The 2020 annual report is outJun 4, 2021

Y-mAbs Therapeutics A/S has published its annual report for 2020. Gross profit came to DKK 82,433,523, and the net result was DKK -1,202,417.

About Y-mAbs Therapeutics A/S

Y-mAbs Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Vincent Sainte-Catherine. The board consists of Antoine Bernasconi (chair), Julien Forest and Vincent Sainte-Catherine. The company is owned by Y-mAbs Therapeutics, Inc.. The company has 13 employees (2026). In 2025, the company reported a gross profit of DKK 29,300,371 and a net result of DKK -38,461,598 compared with DKK -12,500,464 the year before. Equity in the 2025 report amounted to DKK -163,651,844.

Source: annual report 2025, Danish Business Authority